PharmTheon is a drug discovery and development research center dedicated to bridging the gap between fundamental scientific research and new therapies for patients with unmet medical needs.
PharmTheon is part of the IOCB Tech Group, connecting academic and biotech research with innovation, investment, and support for science.
We advance therapeutic discovery by integrating medicinal chemistry, computational and AI-driven drug design, high-throughput screening, and compound optimization with disease biology, assay development, biophysical and functional characterization, target engagement studies, biomarker identification, patient stratification, and in vivo proof-of-concept studies.
We provide medicinal chemistry expertise, including hit identification, computational and AI-driven drug design, hit-to-lead development, structure–activity relationship (SAR) studies, and lead optimization to accelerate small-molecule drug discovery.
We investigate molecular interactions, target engagement, and binding mechanisms using biophysical assays and structural biology approaches, including X-ray crystallography, NMR, and cryo-EM.
We develop biochemical and cell-based assays to validate therapeutic targets, screen and characterize compounds, and evaluate their biological activity. We establish in vivo proof-of-concept studies to assess therapeutic potential.
We identify disease-relevant biomarkers and define target patient populations to guide therapeutic development, inform assay design, and support translational strategies.
We offer flexible collaboration models, including co-development partnerships with shared investment, intellectual property and commercial upside, joint grant-funded programs, and fee-for-service drug discovery. We tailor each partnership to the scientific goals, funding opportunities, and needs of our collaborators.
We identify any patents or proprietary technologies that may interfere with or enhance specific aspects of the project.
We define and assess Go/No-Go (GNG) decision points, including the key data or milestones needed to determine whether the project should proceed, be modified, or be discontinued.
We ensure that all assays used to assess target engagement, functional activity, and therapeutic outcomes are properly validated, reproducible, and meet high-quality standards.
William Lee
Former Executive Vice President of Research at Gilead Sciences
James Lorens
Head of Oncology and a founding scientist at Rigel Pharmaceuticals Inc (RIGL)
Ursula Vogel
Executive Business & Corporate Development Advisor
Vít Perlík
Director of Regulatory Science and Clinical Development in Pharminvent
David Andrews
Ex-Senior Director, Oncology R&D, AstraZeneca
David Smith
Former Open Innovation Programme at AstraZeneca
Štěpán Vyskočil
Chief Scientific Advisor
Daniel Glynn
Project manager
Václav Veverka
Scientific Advisor
Kateřina Tsolov
CFO
Petra Břehová
Head of laboratory
Medicinal Chemistry
Petr Špaček
Automation scientist
Medicinal Chemistry
Ondřej Štěpánek
Senior scientist
Medicinal Chemistry
Peter Urbanovský
Senior scientist
Medicinal Chemistry
Mbilo Misehe
Senior scientist
Medicinal Chemistry
Martin Pošta
Senior scientist
Medicinal Chemistry
Michal Rahm
Junior scientist
Medicinal Chemistry
Marijo Čičak
Junior scientist
Medicinal Chemistry
Matúš Drexler
Data & Automation scientist
Biochemistry
Michal Svoboda
Senior scientist
Biochemistry
Ilona Kalasová
Senior scientist
Cell Biology
Monika Nedomová
Senior scientist
Cell Biology
Veronika Biddle
Senior scientist
Cell Biology
Ondřej Martinec
Senior scientist
Cell Biology
Oksana Tsyklauri
Senior scientist
In Vivo Biology
Pavla Duspiva
Junior scientist
In Vivo Biology
Valeriia Kopytko
Research assistant / Lab manager
Biochemistry
Marion Wendenbaum
Research assistant
Cell Biology
IOCB Tech group transforms cutting-edge scientific discoveries emerging from basic research at the Institute of Organic Chemistry and Biochemistry (IOCB), into real-world solutions by supporting the development of innovative research, fostering biotech entrepreneurship, and bridging the gap between the lab and market. Through commercialization, incubation, and public engagement, we help science grow into impactful technologies that benefit society.
Společnost PharmTheon s.r.o. zveřejňuje upozornění pro věřitele, zástupce zaměstnanců, zaměstnance a společníky na jejich práva v souvislosti s plánovaným rozdělením společnosti IOCB TECH s.r.o. formou vyčlenění sloučením se společností PharmTheon s.r.o.
Big day for PharmTheon at #BioEquity. We talked about how to bring great science to market - and came to a very Czech conclusion: be brutally honest, don’t fear failure, and keep going. The good news? The great science has always been here. The even better news? We’re building an ecosystem that makes it investable. #PharmTheon #TranslationalResearch #Innovation #CzechScience
🧬 A Day in the Life of a Translational Research Center 🧬 At PharmTheon, no two days are ever the same, but they all share one thing - a drive to turn great science into real-world solutions. We’re a team of 18 scientists - 9 chemists and 9 biologists, working side by side in three bold projects: 1. Overcoming treatment limitations to enhance conventional therapies 2. Advancing innovative molecules to support next-generation immunotherapies 3. Designing optimized molecules for sharper and faster diagnostics What does that look like in real life? Scroll through the stunning behind-the-scenes photos by Jana Plavec, Czech Academy of Sciences. #PharmTheon #IOCBTech #TranslationalResearch #DrugDiscovery #Biotech #Innovation #AppliedResearch #ScienceToImpact #CzechScience